SCHEMBL762167

SCHEMBL762167

Cc1cccc2c1n(CCN1CCOCC1)c(=O)n2C(=O)NC1CCCc2ccccc21

nearest known ligand 0.79

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 12/20 0.79
CNR1 P21554 4/20 0.79
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
DRD2 P14416 1/20 0.46
HTR7 P34969 1/20 0.46
TAOK3 Q9H2K8 1/20 0.46
CCR4 P51679 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3386627 0.99 CNR2 (0.78) CNR2CNR1TAS1R3TAS1R1TAS1R2
SCHEMBL737219 0.89 CNR2 (1.00) CNR2CNR1DRD2TAOK3
SCHEMBL4120174 0.89 CNR2 (1.00) CNR2CNR1DRD2TAOK3
Hydrochloric Acid SCHEMBL3390668 0.88 CNR2 (0.98) CNR2CNR1DRD2TAOK3
Hydrochloric Acid SCHEMBL3393278 0.88 CNR2 (0.98) CNR2CNR1DRD2TAOK3
SCHEMBL762165 0.83 CNR2 (0.79) CNR2CNR1DRD2TAOK3LMNA
SCHEMBL737884 0.83 CNR2 (0.89) CNR2CNR1
SCHEMBL737649 0.83 CNR2 (0.89) CNR2CNR1
Hydrochloric Acid SCHEMBL3390684 0.83 CNR2 (0.78) CNR2CNR1DRD2TAOK3LMNA
SCHEMBL762507 0.82 CNR2 (0.87) CNR2CNR1DRD2HTR7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138177-B2 Benzimidazolone derivatives as CB2 receptor ligands PFIZER INC. (US) 2012-03-20 US disclosed
US-8138177-B2 Benzimidazolone derivatives as CB2 receptor ligands PFIZER INC. (US) 2012-03-20 US disclosed
EP-1861377-B1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS PFIZER (US) 2010-12-29 EP disclosed
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES PFIZER INC 2009-12-03 US disclosed
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS ANDO KAZUO 2009-07-16 US disclosed
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS ANDO KAZUO 2009-07-16 US disclosed
WO-2008032164-A2 BENZIMIDAZOLONE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES TRPV1, CNR1, CNR2 CNR2 3/4885CNR1 2/4885TAS1R3 562/4885
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS TRPV1, CNR1, CNR2 CNR2 3/4885CNR1 2/4885TAS1R3 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.